BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32399707)

  • 21. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
    Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
    Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
    Xiong X; Cai Z; Yang J; Shu X
    J Cancer Res Ther; 2015; 11(3):665. PubMed ID: 26458696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
    Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
    Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
    Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
    Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
    Liu T; Zhu F; Xiao Y; Li Q; Liu X; Yang K; Wu G; Zhang L
    Cancer Manag Res; 2018; 10():5061-5069. PubMed ID: 30464606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
    Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
    Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
    Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
    Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of patients treated with SVILE
    Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
    Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
    [No Abstract]   [Full Text] [Related]  

  • 33. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
    Zhang J; Jiang W; Wang WD; Liu CC; Hu YP; Xia ZJ
    Asian Pac J Cancer Prev; 2015; 16(11):4515-20. PubMed ID: 26107196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
    Ahn HK; Kim SJ; Hwang DW; Ko YH; Tang T; Lim ST; Kim WS
    Invest New Drugs; 2013 Apr; 31(2):469-72. PubMed ID: 23108598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
    Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
    BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
    Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
    Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.
    Liang JH; Wang L; Peter Gale R; Wu W; Xia Y; Fan L; Li JY; Xu W
    Blood Cancer J; 2017 Sep; 7(9):e608. PubMed ID: 29016569
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
    Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
    Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.